Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $5.89 and traded as high as $6.47. Lexicon Pharmaceuticals shares last traded at $6.33, with a volume of 6,216 shares traded.

Several analysts have issued reports on LXRX shares. Wedbush set a $175.00 price target on shares of Lululemon Athletica and gave the stock a “hold” rating in a research report on Tuesday, June 11th. ValuEngine downgraded shares of Wolverine World Wide from a “hold” rating to a “sell” rating in a report on Monday, May 20th. BidaskClub downgraded shares of Amyris from a “hold” rating to a “sell” rating in a report on Thursday, June 27th. Needham & Company LLC raised their price objective on shares of Alteryx to $108.00 and gave the stock a “buy” rating in a report on Thursday, May 2nd. Finally, Zacks Investment Research raised shares of HB Fuller from a “sell” rating to a “hold” rating in a report on Wednesday, July 3rd. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $16.38.

The company has a market capitalization of $658.87 million, a P/E ratio of -5.45 and a beta of 0.84. The firm has a 50 day moving average price of $5.90.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.21). The company had revenue of $9.20 million during the quarter, compared to the consensus estimate of $13.26 million. During the same period in the prior year, the firm posted ($0.40) earnings per share. The company’s revenue was down 63.8% on a year-over-year basis. As a group, sell-side analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.47 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers grew its position in shares of Lexicon Pharmaceuticals by 47.3% during the 4th quarter. Rhumbline Advisers now owns 57,193 shares of the biopharmaceutical company’s stock worth $380,000 after buying an additional 18,376 shares during the period. Geode Capital Management LLC grew its position in shares of Lexicon Pharmaceuticals by 2.5% during the 4th quarter. Geode Capital Management LLC now owns 565,085 shares of the biopharmaceutical company’s stock worth $3,752,000 after buying an additional 13,664 shares during the period. Two Sigma Investments LP grew its position in shares of Lexicon Pharmaceuticals by 70.0% during the 4th quarter. Two Sigma Investments LP now owns 313,877 shares of the biopharmaceutical company’s stock worth $2,084,000 after buying an additional 129,215 shares during the period. Two Sigma Advisers LP grew its position in shares of Lexicon Pharmaceuticals by 81.3% during the 4th quarter. Two Sigma Advisers LP now owns 28,416 shares of the biopharmaceutical company’s stock worth $189,000 after buying an additional 12,739 shares during the period. Finally, D. E. Shaw & Co. Inc. grew its holdings in Lexicon Pharmaceuticals by 181.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 268,476 shares of the biopharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 173,096 shares during the period. 98.29% of the stock is owned by institutional investors.

About Lexicon Pharmaceuticals (NASDAQ:LXRX)

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.

Read More: How to interpret a stock’s beta number

Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.